Deepull

Direct-from-blood multiplex PCR targeting 95% of sepsis-causing pathogens

Barcelona, Spain · Founded 2020

Headquarters
Barcelona
Founded
2020
Business Model
B2B
Last Round
Series CApr 2025
Rounds
2

About

Deepull is a Barcelona, Spain-based clinical diagnostics company developing the UllCORE System, a direct-from-blood multiplex PCR platform that identifies sepsis-causing pathogens and antibiotic resistance markers in about one hour, targeting 95% of causative organisms. Led by CEO Jordi Carrera, the company aims to close the diagnostic gap in sepsis care where traditional blood culture testing can take days, and its UllCORE BSI Test has received FDA Breakthrough Device Designation.

Summary

Deepull is a Biotech company based in Barcelona, Spain, founded in 2020. Its most recent funding was a Series C round in Apr 2025. Investors include Columbus Venture Partners, Panakes Partners and Mérieux Equity Partners.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series CSeries CApr 2025

Sign up to see all 2 rounds

Series B through Series C — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Deepull on Indexed.vc
<a href="https://indexed.vc/companies/deepull"><img src="https://indexed.vc/api/badge/company/deepull" alt="Deepull on Indexed.vc" width="260" height="76" /></a>